**2. References**


Obesity Related Lipid Profile and Altered Insulin

Metabolism 2007 Sep;18(7):280-5

Hum Reprod 2003 18: 2289-93

May;85(5):1319-40

44

Incretion in Adolescent with Policystic Ovary Syndrome 13

[17] Wild RA, Painter PC, Counlson PB, Carruth KB, Ranney GB. Lipoprotein lipid

[19] Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP.

[20] Coviello AD, Richard S, Legro, Dunaif A. Adolescent girls with polycystic ovary

[21] Orio F Jr, Palomba S, Cascella T, Tauchmanovà L, Nardo LG, Di Biase S, Labella D,

[23] Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between

[24] Carmina E, Lobo RA. Policystic ovary syndrome (PCOS): arguably the most common

[26] Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ; Dunaif A. Screening for

[27] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.

[29] Mather KJ, Verma S, Corenblum B, Anderson TJ. Normal endothelial function despite

[30] Pasquali R. Obesity and androgens: facts and perspectives; Fertil Steril 2006

[31] Brown GA, Vukovich MD, Martini ER, Kohut ML, Franke WD, Jackson DA, King DS.

Journal of Clinical Endocrinology and metabolism 2000 Nov;85(11):4074-80

ovary syndrome? Reprod Biomed Online Journal. 2004 Nov;9(5):505-10 [22] Lewy UD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in

Clinical Endocrinology and metabolism 2006 Feb;91(2):492-7.

Clinical Endocrinology and metabolism 1999 84:1897-1899

of Clinical Endocrinology and metabolism 2002 87:1017-1023

Clinical Endocrinology and metabolism 1960 21:1440 – 1447

Clinical Endocrinology and metabolism 2000 May;85(5)

[25] Piccione E, Dei M Donna Domani, CIC Edizioni Internazionali

Journal of Clinical Endocrinology and Metabolism 1985; 61,946-51 11. [18] Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the

variables. Clinical Endocrinology 1994; 41: 463-71

concentrations and cardiovascular risk in women with Policystic ovary syndrome.

Policystic ovary syndrome:relation to anthropometric, endocrine and metabolic

Patophysiology and types of dylipidemia in PCOS, Trends in Endocrinology and

syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. Journal of

Russo T, Savastano S, Tolino A, Zullo F, Colao A, Lombardi. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic

adolescent girl with polycystic ovarian syndrome. Journal of Pediatric 2001 138: 38-

American and Italian women ith polycystic ovary syndrome: influence of the diet.

endocrinopathy is associated with significant morbidity in women. Journal of

abnormal glucose tolerance in adolescents with polycistic ovary syndrome. Journal

Homeostasis model assessment: insulin resistence and βcell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28; 412-419 [28] Ferriman D, Gallwey JD. Clinical Assesmentof body hair growth in women. Journal of

insulin resistance in healthy women with the polycystic ovary syndrome. Journal of

Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men.


[4] Franks S. Policystic ovary syndrome. The New England Journal of Medicine 1995 333:

[5] Ehrmann DA, Barnes RB, Rosenfield RI, Cavaghan MK, Imperial J. Prevalence of

[6] Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Human. Reproduction. Update 2005 11, 631-643 [7] Diamanti-Kandarakis E, Piperi C, Spina J, Argyrakopoulou G, Papanastasiou L, Bergiele

[8] Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery

[9] Teimuraz Apridonidze, Paulina A. Essah, Maria J. Iuorno and John E. Nestler.

[10] Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese

[11] Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, Lombardi G, and Lobo

[12] Fulghesu AM, Angioni S, Portoghese E. Milano F, Batetta B, Paoletti AM, Melis GB.

[13] Chang RJ, Nakamura RM, Judd HL, & Kaplan SA. Insulin resistence in nonobese

[14] Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, & Tapanainen JS.

[15] Dunaif A, Graf M, Mandeli J, Laumas V, & Dobrjansky A. Characterization of group of

[16] Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG,

syndrome. Diabetes Care 1999 22: 141-14626.

Endocrinology (Oxf) 1992 37: 119-125

2005 Apr;90(4):1929-35

Dec;92(12):4609-14

2000 15, 1266-1274

65, 499-507

genetics factors. Hormones (Athens) 2006 5, 17-3428.

Journal of Endocrinology 2005 Mar;152(3):389-94

and Sterility. 2006 Aug;86(2):398-404

Metabolism 1983 57, 356-359 7.

and Metabolism 1999 84, 4006-4011

impaired glucose tollerance and diabetes in women with Policystic ovary

A, Panidis D. Polycystic ovary syndrome: the influence of environmental and

disease in lean and obese women with the polycystic ovary syndrome. Clinical

Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and metabolism

women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. Journal of Clinical Endocrinology and metabolism 2007

RA. Evidence of altered adipocyte function in policystyc ovary sindrome. European

Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome. Fertility

patients with Policystic ovarian disease. Journal of Clinical Endocrinology and

Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with Policystic ovary syndrome.Human Reproduction

hyperandrogenic women with acanthosis nigricans impaired glucose tolerance, and/or hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 1987

Zapanti Ed, & Bartzis MI. A survey of the Policystic ovary syndrome in the greck island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology

853-861


**2** 

*1,4Finland 2,3China* 

**Ethnic Difference in Lipid Profiles** 

Dyslipidaemia is a major cardiovascular disease (CVD) risk factor that plays an important role in the progress of atherosclerosis, the underlying pathology of CVD. To keep lipids and lipoproteins levels within ideal range has been recommended by different national, regional, or global (2001; Graham et al. 2007; World Health Organization 2007) guidelines on the prevention and management of CVD. The prevalence and pattern of lipid disorder,

As a component of the metabolic syndrome, dyslipidaemia often coexists with diabetes, the coronary heart disease (CHD) risk equivalent. An atherogenic lipid profiles consists of high triglycerides (TG) and small dense low-density lipoprotein cholesterol (LDL-C) and low high-density lipoprotein cholesterol (HDL-C). The importance of dyslipidaemia on risk of CVD in patients with diabetes has been extensively studied in numerous studies. Reduced HDL-C is well documented as an independent predictor of CVD events (Wilson et al. 1988; Cooney et al. 2009). In contrast, the role of TG as an independent risk factor for CVD is more controversial (Patel et al. 2004; Psaty et al. 2004; Barzi et al. 2005; Sarwar et al. 2007; Wang et al. 2007). Recently, the interest to use novel parameters such as total cholesterol (TC) to HDL ratio (TC/HDL-C), non-HDL-cholesterol (non-HDL-C), apolipoprotein B (apoB) and apolipoprotein A (apoA) to assess CVD risk has increased (Barzi et al. 2005; Pischon et al. 2005; Charlton-Menys et al. 2009). As a CVD risk predictor, the non-HDL-C has been considered to be superior to LDL-C (Cui et al. 2001; Schulze et al. 2004; Liu et al. 2005; Ridker et al. 2005). However, there are racial and geographic disparities in lipid profiles not only in general populations but also in individuals with different glucose categories. The Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP-ATP III) has recommended that certain factors be recognized when clinicians evaluate the lipid profile of different population groups (Adult Treatment Panel III 2002). Although management of lipids using NCEP-ATP III guidelines is applicable to all populations, unique aspects of risk factor profile call for special attention to certain

**1. Introduction** 

however, differ between ethnicities and populations.

features in different racial/ethnic groups.

Lei Zhang1,2,3,4, Qing Qiao1,4 and Yanhu Dong2,3

*1Hjelt Institute, University of Helsinki, Helsinki, 2Qingdao Endocrine & Diabetes Hospital, Qingdao,* 

*<sup>4</sup> National Institute for Health and Welfare, Helsinki,* 

*3Weifang Medical University, Weifang,* 

[32] Tan KC, Shiu SW, Kung AW.Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy. Clinical Endocrinology (Oxf) 1999 51, 765-769
